A Form 25 will be filed by NASDAQ with the US Securities and Exchange Commission to complete the delisting, which will become effective ten days after the filing.

No further details were disclosed.

Comments on this story may be sent to admin@m2.com

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the listing or trading of Favrille's common stock on the OTC Bulletin Boards, Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the listing status of Favrille's common stock on the OTC Bulletin Boards, Favrille's ability to continue its operations, conserve cash or recognize value on its assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

SOURCE Favrille, Inc.

http://www.favrille.com

SOURCE: The NASDAQ OMX Group, Inc.

For more information about The NASDAQ Stock Market, visit the NASDAQ Web site at http://www.nasdaq.com. NASDAQ's rules governing the delisting of securities can be found in the NASDAQ Rule 4800 Series, available on the NASDAQ Web site: http://www.cchwallstreet.com/NASDAQTools/bookmark.asp?id=nasdaq-rule_4800&manual=/nasdaq/main/nasdaq-equityrules/.

Favrille is a biopharmaceutical company developing targeted immunotherapies for the treatment of cancer. The company''s proprietary manufacturing technology for the cost effective production of active immunotherapy products designed to stimulate a patient''s immune system to mount a specific and sustained response to disease.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company is also developing applications based on its immunotherapy expertise and proprietary manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. Additionally, it acquired a series of optimized anti-CD20 antibodies from Diversa Corporation (now Verenium Corporation) in June 2007 to develop next-generation treatment approaches for B-cell NHL.

The company has not recorded revenues since its inception in 2000 mainly due to the lack of marketed products and collaborative partners. However, the company is forecast to record revenues of $48 million by 2010 from Specifid US sales and royalties on non-US sales.

Reasons to Purchase

Access all the important information and analysis on the company in a single report

Understand company''s strengths, weaknesses, opportunities and threats along with business strategy and value chain

Gain access to company''s adjusted five year financial data along with key ratios and market capitalization

http://www.companiesandmarkets.com/information.asp?id=K60FM45H745983

CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 (0)1933 674 780 Fax: +44 (0)1933 674 780 e-mail: info@companiesandmarkets.com WWW:http://www.companiesandmarkets.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.